Physician profile
Eric Chudej
NPI 1053620013
$1,755.32
in general payments reported to CMS, 2019-2025
27 companies · $1,204 in 2025
The $1,204 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.58 · 2021: $16.55 · 2023: $124 · 2024: $348 · 2025: $1,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,675.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $246.23 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $196.23 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $167.31 | 2019-2025 | |
| Abbvie INC. | $163.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $139.82 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $114.90 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.93 | 2024-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $82.45 | 2025 | Zoryve |
| Sumitomo Pharma America, INC. | $77.99 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.93 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $57.14 | 2023-2025 | Arexvy, Shingrix |
| Dexcom, INC. | $55.60 | 2023-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $44.68 | 2024-2025 | Voquezna |
| Vertex Pharmaceuticals Incorporated | $28.05 | 2025 | |
| Sanofi-Aventis U.S. LLC | $21.57 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $20.58 | 2024 | Azstarys |
| Amneal Pharmaceuticals LLC | $19.98 | 2024 | Rytary |
| Amarin Pharma, INC. | $18.67 | 2019 | |
| Astellas Pharma US INC | $18.64 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $16.78 | 2025 | |
| Axsome Therapeutics, INC. | $16.71 | 2025 | Symbravo |
| Dynavax Technologies Corporation | $16.43 | 2025 | Heplisav-B |
| Lundbeck LLC | $14.87 | 2025 | Rexulti |
| Amgen INC. | $14.57 | 2025 | Otezla, Repatha |
| Ipsen Biopharmaceuticals, INC | $13.99 | 2024 | Bylvay |
| Novartis Pharmaceuticals Corporation | $13.73 | 2019 | |
| Organon LLC | $6.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Chudej listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.